Since the record-breaking first- year sales of celecoxib (Pharmacia/Pfizer's Celebrex) and rofecoxib (Merck's Vioxx), cyclooxygenase-2 (COX-2) inhibitors have emerged as a major target of clinical investigation in several therapeutic areas. Market Outlook for COX-2 Inhibitors, a new study from Decision Resources, Inc., estimates that the market for COX-2 inhibitors will more than triple by 2010. This expansion will be driven by the launch of second-generation COX-2 inhibitors, the introduction of COX-2 inhibitors in the Japanese market, the careful positioning of second-generation agents, and regulatory approval of COX-2 inhibitors for new indications.

  (Photo: )    Report in brief 

This study evaluates the market for COX-2 inhibitors in five indications: osteoarthritis; rheumatoid arthritis; moderate to severe chronic low back pain; colorectal cancer; and mild cognitive impairment. The report starts by describing the role of COX-2 in various disease mechanisms involved in the five indications under study. Next, it reviews the epidemiology of these five conditions and estimates target populations for drug therapy. The report discusses the safety and efficacy of celecoxib and rofecoxib as well as prescribing patterns for these agents in the seven major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). The study also offers in-depth analysis of unmet clinical needs and the emerging agents that may one day address them. Finally, it presents the market outlook and opportunity for COX-2 inhibitors in the five indications during a 2000-2010 study period.

Market Outlook for COX-2 Inhibitors offers invaluable strategic intelligence for companies competing in this market. This study is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at

Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or

In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553, or

Off-Label Usage of Antipsychotic Drugs Will Drive Significant Market Growth, According to a Decision Resources Study

View Now